Praxis Precision Medicines to Participate in Upcoming Conferences

About this update from Praxis Precision Medicines, Inc.

BOSTON , May 20, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX ), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that it will be participating in three upcoming investor conferences: Praxis management will be participating in a fireside chat at the H.C. Wainwright 3 rd Annual BioConnect Investor Conference , taking place at NASDAQ on Tuesday, May 20 th, at 9:30am ET . A webcast of the fireside chat will be available through this link . Praxis management will also be participating in the Mizuho Neuro & Ophthalmology Summit, taking place in New York City on Wednesday, May 21 st. Praxis management will also be presenting a corporate overview at the Jefferies Global Healthcare Conference , taking place at the Marriott Marquis in New York City on Wednesday, June 4 th, at 8:10am ET . A live webcast of the presentation will be available through this link . The Company will be available for one-on-one meetings during all events. Interested investors should contact their respective representatives to request meetings. Replays of the webcasted events will also be available through the “ Events & Presentations ” page under the “ Investors + Media ” section of the company’s website for 90 days. About Praxis Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying genetic insights to the discovery and development of therapies for rare and more prevalent neurological disorders through our proprietary small molecule platform, Cerebrum™, and antisense oligonucleotide (ASO) platform, Solidus™, using our understanding of shared biological targets and circuits in the brain. Praxis has established a diversified, multimodal CNS portfolio including multiple programs across epilepsy and movement disorders, with four clinical-stage product candidates. For more information, please visit www.praxismedicines.com and follow us on Facebook , Instagram , LinkedIn and Twitter/X . Investor Contact: Praxis Precision Medicines [email protected] 857-702-9452 Media Contact: Dan Ferry Life Science Advisors [email protected] 617-430-7576 Source: Praxis Precision Medicines, Inc.

View stock analysis, news, and events for Praxis Precision Medicines, Inc.